Bloodstream Infection Testing Market Projected to Reach $1.4 B Globally by 2035

The global bloodstream infection testing market was valued at roughly $876 million in 2025 and is forecast to grow to about $1.4 billion by 2035, reflecting a compound annual growth rate of 4.8% for the 2026‑2035 period. Growth is driven by rising incidences of sepsis and hospital‑acquired infections, increasing numbers of immunocompromised patients, and expanding adoption of rapid molecular diagnostics and antimicrobial‑stewardship programmes.

Blood culture remains the dominant segment, accounting for roughly 79% of the market in 2025, while whole‑blood molecular testing is expected to post the fastest CAGR. Molecular diagnostics are gaining market share as multiplex PCR and next‑generation platforms deliver same‑day pathogen identification and resistance profiling.

In North America, the market was estimated at $3.8 billion in 2024 and is projected to reach $6.38 billion by 2032 (CAGR 6.7%). The United States leads the region, supported by a robust healthcare system and high uptake of automated and rapid testing methods. Key players across both markets include Becton‑Dickinson, Thermo Fisher Scientific, bioMérieux, Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, and Danaher‑owned Cepheid, among others.